0

WHY THIS MATTERS IN BRIEF

What if pharmacies and doctors weren’t in a remote building somewhere but in your body instead?

 

Love the Exponential Future? Join our XPotential Community, future proof yourself with courses from XPotential University, read about exponential tech and trendsconnect, watch a keynote, or browse my blog.

New research presented at the American Society for Pharmacology and Experimental Therapeutics annual meeting has demonstrated the potential for genetically engineered bacteria to be an effective Parkinson’s disease treatment. In a world first, and a hat tip to the in vivo living pharmacies of the future, aptly called living pharmacies, which will let our own bodies detect the disease and make the cures in vivo, the researchers created a bacteria that can synthesize a consistent source of medicine inside a patient’s gut, and animal tests have demonstrated it is safe and effective.

 

RELATED
Meet Ross, the world's first AI lawyer

 

The idea of engineering bacteria to serve as medical treatments is not new. For years scientists have experimented with ways of modifying bacteria to fit our needs, from genetically engineering bacteria to eat up excess ammonia in a human body to helping bacteria hunt down colorectal cancer cells, as well as creating all kinds of other implantable devices that can identify and treat diseases in vivo such as caner.

Of course, before an idea like this is ready for mainstream clinical uses a number of hurdles need to be overcome. It’s one thing to offer a patient controlled doses of a drug via a pill, but limiting the growth of living microbes in their bodies that are engineered to synthesize those same therapeutic molecules in the human gut is a whole different challenge.

New research from a team of scientists has presented an incremental step forward in engineering a novel strain of the human probiotic E.coli Nissle 1917 that has been developed to continually synthesize a Parkinson’s disease drug known as L-DOPA.

 

RELATED
Synthetic proteins with "unlimited potential" usher in new era of smart cell therapies

 

L-DOPA is a molecule that acts as a precursor to dopamine and it has been the gold-standard treatment for Parkinson’s patients for decades. Doctors have found that after around five years of L-DOPA treatment patients often develop side effects known as dyskinesias. These side effects are thought to be related to the lack of a continuous source of the drug to the brain.

So to address this problem the new research explored whether bacteria producing L-DOPA in the gut could result in a consistent delivery of the drug to the brain. Piyush Padhi, a researcher working on the project, said the engineered bacteria eat up a molecule called tyrosine and spit out L-DOPA.

“After several iterations and improving gut microbiome-based drug delivery technology, we have developed a gut-healthy probiotic bacteria that can produce stable levels of L-DOPA in a way that can be highly tuned to deliver the dose required for each patient,” Padhi explained.

 

RELATED
Worlds first designer baby is born in Mexico and has three parents

 

Several mouse studies demonstrated that the engineered bacteria resulted in steady, consistent blood concentrations of L-DOPA. Then experiments with Parkinson’s disease animal models found the treatment led to improved motor and cognitive functions, indicating the engineered bacteria were producing therapeutically effective volumes of the drug.

The researchers also claim the levels of L-DOPA produced by the bacteria can be finely controlled. This can be done by either limiting the daily doses of bacteria consumed in capsules or by modulating consumption of a sugar called rhamhose. This rare sugar is needed by the bacteria to go on and produce L-DOPA.

Anumantha Kanthasamy, another researcher working on the project, said the team is working on adapting the approach to treat other diseases that require continual measured doses of drugs. The next step is optimizing the engineered bacteria as the research looks to human trials.

 

RELATED
Under the skin of Ross the worlds first AI lawyer

 

“We are hoping that our continuous, non-pulsatile microbial-based delivery method for L-DOPA limits the development and progression of levodopa-induced dyskinesia,” said Kanthasamy. “We are currently exploring using this approach to deliver treatments for other conditions such as Alzheimer’s disease and depression and are in process of initiating FDA approval for clinical testing of this novel gut microbiome therapeutic technology.”

The new research has yet to be published in a peer-reviewed journal but was recently presented at the American Society for Pharmacology and Experimental Therapeutics annual meeting during the Experimental Biology (EB) 2022 meeting in Philadelphia.

Source: Experimental Biology

About author

Matthew Griffin

Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.

Your email address will not be published. Required fields are marked *